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US FDA RELEASES FINAL RULE ON MEDICAL
DEVICE DATA SYSTEMS - WHAT DOES THIS
MEAN FOR DEVICE MANUFACTURERS?
Abstract
On 16 April 2011, the US Food and Drug Administration’s (FDA’s) final rule on medical
device data systems (MDDSs) came into force. This rule attempts to remove the
uncertainty surrounding the safety classification of certain information technology
systems used in healthcare. Devices that now meet the criteria of being an MDDS are
classified as Class I (general controls). However, this final ruling explicitly precludes
specific software applications that meet the definition of an MDDS, such as electronic
health record applications and computerised physician order entry applications, as
being beyond the scope of an MDDS. Similarly, ambiguity still remains surrounding
mobile device applications. The purpose of this article by Martin McHugh, Fergal
McCaffery and Valentine Casey is to provide an overview of the FDA’s final rule on
the safety classification of an MDDS, how this rule has been amended in comparison to
the proposed rule and what this rule means for MDDS manufacturers. In addition, the
authors will be discussing the challenges medical device manufacturers face in the
changing regulatory environment.

Introduction
In 2009, the Consumers Union produced a report entitled, To Err is Human - To Delay is
Deadly1, stating that over 100,000 people die annually as a result of preventable medical
harm (i.e. failure of a planned action to be completed as intended or the use of the
wrong plan). A number of these deaths are attributable to medical device software
failures, such as the deaths of 21 Panamanian teletherapy patients in 20002.
Unfortunately, it is not only failures in medical devices containing embedded software
that can have fatal consequences for patients. In 2009, six patients died and hundreds of
adverse events occurred due to errors with Hospital Information Technology (HIT)3. A
report completed by The Huffington Post Investigative Fund4 identified 237 adverse
events associated with HIT over a two-year period. The majority of these problems
centred on computerised medical ordering software and systems that supply the
software with vital information such as patient medication dosages. Software is used
widely within healthcare and examples include:
•
•
•
•
•

embedded software in a medical device;
standalone software as a medical device;
HIT;
mobile device software; and
software used to develop medical devices.

However, as the reliance on software-controlled devices for use in healthcare increases,
regulatory control is needed to ensure that medical devices either consisting entirely of
software or having a software component are safe. Software used in healthcare falls into
one of four categories:

•
•
•
•

software
software
software
software

as an accessory to a medical device;
as a medical device in its own right;
as a medical device data system (MDDS); or
currently unclassified and not subject to specific regulations.

The category into which software falls is dependent on the function that it performs.
Regulatory controls have previously been put in place to regulate both medical devices
and accessories to medical devices. However, no specific guidance had been provided in
relation to the usage of devices that are now classified as MDDSs. These devices were
either previously unclassified, classified as accessories to medical devices or medical
devices in their own right. The US Food and Drug Administration (FDA) describes an
MDDS as being any electronic device used to transfer, store, convert or display medical
data that is not intended for active patient monitoring.
In 1981, the FDA began to investigate the use of software in healthcare. Initially
the FDA classified medical device software based upon its Draft Software Policy,
published in 1987 and revised in 1989 (now withdrawn). However, since then the rate at
which computer and software-based products are used in healthcare has grown
exponentially. Prior to 16 April 2011, devices that now meet the current definition of
being an MDDS were classified as either a Class III device (potentially high risk) or
assumed the safety classification of the parent medical device to which they were
connected, although the FDA had been operating under its discretionary enforcement
policy and therefore had not been enforcing the Class III requirements on all MDDSs5.
On 16 April 2011, the FDA rule became effective that classified an MDDS as a Class I,
510(k)-exempt medical device6. This ruling came three years after the proposed ruling
was issued on 8 February 20087. This final classification modifies Title 21 of the Code of
Federal Regulations (21 CFR) Part 880.6310 and describes an MDDS as being:
‘software, electronic or electrical hardware such as a physical communications
medium
(including
wireless
hardware),
modems,
interfaces,
and
a
communications protocol’.
The purpose of this article is to provide an overview of the FDA’s final rule on the safety
classification of an MDDS, how this rule has been amended in comparison to the
proposed rule and what this rule means for MDDS manufacturers. In addition, the
authors outline the challenges which medical device developers face when developing
safe, reliable devices that conform to the latest regulatory requirements.

Scope of the MDDS classification
Although this ruling has been developed to provide clarity on the regulation of devices
that come under the heading of being an MDDS, it has created a level of confusion
among manufacturers. Confusion surrounds areas such as device classification, active
patient monitoring and the transfer of medical data. This is evident in the comments
section of the ruling6.
Previous classification

An MDDS is an example of a post-amendment device. Post-amendment devices are
devices that were not actively manufactured or sold prior to 28 May 1976. All postamendment devices were automatically classified as Class III devices until they are
reclassified as either Class I or Class II devices. They are deemed to place the patient,
clinician or third party at the most potential risk of harm. Devices actively manufactured
or sold before 28 May 1976 are known as pre-amendment devices. This was the date of
an amendment to the Federal Food, Drug and Cosmetics Act (FFD&C Act).
MDDS classified devices
An MDDS is described in 21 CFR Part 880.6310 as:
‘[A] device that is intended to provide one or more of the following uses, without
controlling or altering the functions or parameters of any connected medical
devices:
(i) The electronic transfer of medical device data;
(ii) The electronic storage of medical device data;
(iii) The electronic conversion of medical device data from one format to another
format in accordance with a preset specification; or
(iv) The electronic display of medical device data.
If a device meets these requirements it can be classified as an MDDS and receives a
safety classification of Class I (general controls). However, if a device meets these
requirements and also performs additional functionality, such as active patient
monitoring, it cannot be considered an MDDS. Devices performing active patient
monitoring assume the safety classification of the parent medical device or automatically
receive a Class III classification until reclassified by the FDA.
Software as an MDDS
While this ruling includes the use of software in healthcare, not all software can be
considered an MDDS. The function performed by the software determines whether or not
it comes under the umbrella of being an MDDS.
The FDA has determined that the risk associated with an MDDS originates from
inadequate software quality and incorrect functioning of the device. It is envisaged that
issues with software that could potentially cause harm would be identified and resolved
by the use of a Quality Management System (QMS) as required by the Quality System
Regulations (QSR). Examples of software as an MDDS include:
•
•
•
•
•

software used to pass a control signal to an infusion pump;
software that stores patient data such as blood pressure readings for review at a
later time;
software that converts digital data generated by a pulse oximeter into a format that
can be printed;
software that displays a previously-stored electrocardiogram for a particular patient;
software used in healthcare labelled as an MDDS that has been modified in
accordance with the manufacturer’s guidelines.

Previously unclassified devices

As part of the final rule regarding MDDSs, device manufacturers that were previously
unregulated and consequently unclassified are now potentially subject to FDA
enforcement if their device meets the definition of an MDDS. Companies that fall into
this category are likely to be smaller manufacturers who are less prepared than larger
companies in terms of having the necessary QMS in place8.
Medical data transfer
Part of the MDDS rule states that devices that transfer data but do not alter the content
are considered MDDSs. The ruling states6:
‘Use of an MDDS for conversion is limited to translation, so that data can be
viewed or transmitted in the same form that it was received by the MDDS’.
Examples of translation include converting data into different languages so as to be
interpreted by equipment supplied by different vendors. Another example is converting
information in HL7 [Health Level 7] format to allow it to be displayed in a spreadsheet.
In essence, an MDDS cannot interpret, analyse or modify clinical data in any way.
Mobile device software
The amount of mobile device software used in healthcare is increasing. The Apple Apps
store has an entire section containing over 230 healthcare applications9. As part of the
final rule, mobile device software theoretically comes under the heading of being an
MDDS provided that it is not used for active patient monitoring. As part of the proposed
rule, a device could only be considered an MDDS when used by a healthcare professional
exclusively10. However, as part of the final rule, a device can be considered an MDDS if
used by either a healthcare professional or a lay person. This change means all medical
device applications used on any mobile platform are subject to regulatory conformance.
However, mobile application developers are avoiding regulatory scrutiny by stating that
their software is neither for patient monitoring nor diagnosis11. Whilst manufacturers and
developers are attempting to avoid the need for regulatory conformance, this loophole
seems set to be closed by the FDA12.

Beyond the scope of the MDDS classification
As part of the final rule on MDDSs, a number of devices - both hardware and software
units that appear to satisfy the criteria for being an MDDS - are beyond the scope of the
MDDS classification. Within this section the authors provide a few examples of such
devices.
Network infrastructure
Whilst HIT utilises network infrastructure, this infrastructure does not necessarily meet
the criteria of being an MDDS. Network infrastructure beyond the scope of the MDDS
ruling includes13:
•
•
•
•

network
network
wireless
network

routers;
hubs;
access points;
attached storage;

•

storage area networks.

It is clear to see that these devices do perform functions associated with that of an
MDDS (i.e. store, transmit or display clinical data). However, they are not developed
solely for that purpose and are considered general information technology within a
hospital environment.
Software not an MDDS
When the proposed rule was issued, a number of comments arose in relation to software
applications used daily in healthcare and whether these software applications would be
considered an MDDS. Software applications such as electronic health records (EHRs) and
computerised physician order entry (CPOE) are deemed beyond the scope of an MDDS.
The reason cited by the FDA in the final ruling (Section III, Comment 7) for this decision
is two-fold. First, whilst it appears that an EHR is used to store clinical data, that data
must have been either obtained electronically from a medical device or the clinical data
stored must be intended for electronic transmission. Second, as with CPOEs, EHRs can
potentially order tests for patients. This would lead to the software falling outside the
scope of an MDDS as it would be initiating the generation of clinical data.
Also, commercial off-the-shelf (COTS) software not developed to perform the
function of an MDDS is not considered an MDDS. This also applies to COTS software that
has been modified within the parameters of the developer’s guidelines.
Alarms
The area of alarm classification as part of the MDDS ruling has created ambiguity among
manufacturers. Alarms connected to a medical device that emit warnings based on the
information received from the connected medical device are typically considered
accessories to the parent device as they are utilised for active patient monitoring.
Essentially, the sounding of an alarm would result in immediate corrective action being
taken in regard to patient treatment.
However, not all alarms fall beyond the scope of an MDDS. Alarms used to
monitor the state of an MDDS are considered to be an MDDS and receive a Class I safety
classification.

Challenges
One of the main challenges for medical device software companies is to understand the
current state of their software development processes in relation to the requirements of
the medical device regulations (e.g. the FDA ruling on MDDSs) and standards. To
achieve this understanding, adherence to the latest development standards is required.
However, current software development standards such as IEC 62304: 2006, Medical
device software - Software life cycle processes were developed prior to the recent
changes in regulatory requirements and as such do not cater for these changes.
Another challenge for medical device companies is in relation to supplier
selection. As medical device manufacturers are responsible for the safety of their medical
devices, it is essential that they are confident that the software (either as a component
of a medical device, as an accessory to a medical device, as a standalone medical
device, or as an MDDS) is developed by following defined and approved processes.
Hence, whenever the software development component of the medical device is

outsourced by the medical device manufacturer it is vital that the manufacturer is
confident that safe and effective software will be delivered that has been created through
adopting regulatory-compliant software development processes. This therefore presents
a challenge for both medical device manufacturers in relation to selecting a software
development organisation and also for software development organisations to become
recognised medical device software suppliers.

What next?
International medical device regulations
Whilst the MDDS final rule aims to remove ambiguity surrounding the use of different
hardware and software in a healthcare environment, confusion still surrounds some
applications of software in healthcare (i.e. EHRs, CPOE and mobile applications). There
are informal reports that the FDA is currently drafting guidance to define what aspects of
health information technology are considered medical devices (e.g. EHRs and CPOE)14.
In a workshop carried out by the FDA, Margaret Hamburg, Commissioner of Food and
Drugs at the FDA, stated that in July 2010 the FDA began drafting a guidance document
on mobile health devices and applications12. This document is expected to be published
soon.
On 21 March 2010, the latest amendment to the European Medical Devices
Directive came into force15. One of the changes introduced was the explicit inclusion of
software into the definition of a medical device16. This extended to the use of standalone
software as an active medical device. However, this inclusion created uncertainty as to
what software would and would not be considered a medical device. An example of such
software includes EHRs and HIT applications. A MEDDEV document is expected to be
released later this year to provide clarity as to what category different types of
healthcare software belong to.
Following the FDA’s release of the final MDDS rule, the European Commission has
determined that specific guidance is required for these systems and a meeting of the
Medical Device Expert Group has been provisionally scheduled for 30 November 2011
and 1 December 2011 to discuss this issue.
Medical device development standards
As discussed, the current standard for the development of medical device software is IEC
62304. The most recent version was released in 2006, prior to the latest regulatory
changes in both Europe and the USA. Consequently, it is not sufficiently comprehensive
to provide guidance in the development of all types of software used to diagnose,
monitor and treat patients. However, IEC 62304 is currently under revision and when a
new version is released, it is expected that it will provide the necessary guidance to
medical device developers develop software for use in healthcare that meets the latest
regulatory requirements.

Conclusions
Prior to 16 April 2011,in the US all post amendment devices utilising software, used in
connection with patient treatment automatically received a Class III safety classification
or adopted the safety classification of the medical device to which it was connected. This
classification could only be changed upon application to the FDA. However on 16 April
2011, the FDA’s final rule governing the use of MDDSs became effective. This ruling

classified device’s that were used for storing, displaying, transmitting or translating
clinical data as Class I devices. However, a caveat was added to the final rule that if a
device performs an additional function such as active patient monitoring it would not
meet the definition of being an MDDS and would be subject to different regulatory
requirements. An MDDS can be hardware, software or a combination of both. As part of
this ruling, manufacturers must adopt a QMS and adhere to the FDA’s general controls.
The reason cited for this is that the FDA envisages any flaws associated with an MDDS
would be software related and would be identified by adopting a QMS. To develop safe
software that meets regulatory requirements, adherence to the latest development
standard is encouraged. Unfortunately, the current development standard (IEC 62304)
was developed prior to this ruling and therefore does not take the changes as part of this
ruling into account.
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Medi SPICE is currently being developed by the Regulated Software Research Group
(RSRG) at Dundalk IT in association with the SPICE User Group. Medi SPICE aims to
provide an end to end software development framework for medical device software
developers to develop safe medical devices that conform to the latest regulatory
requirements and to streamline the process of supplier selection.
Medi SPICE is a software process assessment model for the medical device
industry that is based upon the structure of the International standard for software
process assessment and capability determination (ISO/IEC 15504-51) and provides
coverage of the medical device regulatory device software regulations (with a particular
focus upon the IEC 62304 standard).

